Pediatric Benign Neutropenia: Assessing Practice Preferences in Canada

J Pediatr Hematol Oncol. 2022 Aug 1;44(6):318-322. doi: 10.1097/MPH.0000000000002427. Epub 2022 Feb 4.

Abstract

Pediatric benign neutropenia is a self-limited condition with a benign clinical course. An approach to this condition is not well-defined in the literature. Our objective was to use a case-based survey to elucidate trends in the diagnosis and management of benign neutropenia among pediatric hematology/oncology practitioners in Canada. We received 46 completed surveys (response rate 66%). At initial presentation with fever and neutropenia, 67% of respondents recommended partial septic workup but 11% recommended no investigations. Nearly 70% recommended admission for empiric intravenous antibiotics, while 24% would discharge home without antibiotics. In a patient with fever and known neutropenia, respondents were more likely to pursue outpatient antibiotic therapy. For investigation of chronic neutropenia, most respondents (60%) do not use antineutrophil antibody testing. Common indications for bone marrow biopsy were severe infection, prolonged neutropenia, or before initiating granulocyte colony stimulating factor. Indications for granulocyte colony stimulating factor were based on severity and frequency of infection. Most respondents (84%) would not recommend antibiotic prophylaxis. Results demonstrate the considerable variability in management of benign neutropenia among pediatric hematology/oncology practitioners in Canada and highlight the need for prospective studies to establish diagnostic criteria for benign neutropenia and evaluate management of fever in this population.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Fever / drug therapy
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Neutropenia* / drug therapy
  • Prospective Studies

Substances

  • Anti-Bacterial Agents
  • Granulocyte Colony-Stimulating Factor